The transthyretin amyloid cardiomyopathy treatment market consists of therapies and drugs used for treating transthyretin amyloid cardiomyopathy. Transthyretin amyloid cardiomyopathy is a type of amyloidosis that affects cardiac muscles due to deposition of abnormal transthyretin protein fibrils. It causes stiffening of heart muscles, decreased ejection fraction, heart failure and arrhythmias. The current treatment approaches include medications such as tafamidis and diflunisal that help in stabilizing the deposited transthyretin protein. Other supportive therapies include chemotherapy, stem cell or cardiac transplant depending on severity of the condition. The increasing awareness about novel treatment options and rising prevalence of cardiac disorders due to aging population are fueling the growth of global transthyretin amyloid cardiomyopathy treatment market.
The Global transthyretin amyloid cardiomyopathy treatment
market is estimated to be valued at US$
1943.69 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Transthyretin
Amyloid Cardiomyopathy Treatment Market Demand are DermaSweep Inc.,
Lifetrons Switzerland AG, Trophy Skin, Silk€TMn, HoMedics USA LLC, PMD Beauty,
Dermaglow, ImageDerm Inc., Clairderm Medical Aesthetics, Sylvan Company, Altair
Instruments, Koninklijke Philips, Microderm GLO Skincare USA, Silhouet-Tone,
and Edge Systems LLC. (HydraFacial). These players are investing in R&D of
novel therapeutics and drugs to expand their product portfolio.
The key opportunities in transthyretin amyloid cardiomyopathy treatment market
include expanding access to novel therapies in developing regions, increased
research on gene therapies, and strategic collaborations between pharmaceutical
companies and research institutes.
Major companies are focusing on global expansion through regulatory approvals
and establishing manufacturing facilities in high growth markets like Asia
Pacific and Latin America. For instance, Diflunisal received FDA approval for
ATTR-CM treatment in 2021 and will be commercialized globally.
Market Drivers and Restraints
Market drivers such as rising geriatric population susceptible to cardiac
disorders, availability of several treatment options and increasing treatment
seeking rate are fueling the growth of transthyretin amyloid cardiomyopathy
treatment market. As per WHO, cardiovascular diseases are the leading cause of
mortality worldwide and affect mainly elderly. This ageing demographic is
positively impacting the adoption of treatment.
However, factors like high cost of novel drugs, lack of awareness in low and
middle income countries and long approval timelines are challenging the market
growth. Also, diagnostic difficulties due to non-specific amyloidosis symptoms
pose a restraint. Further research is warranted to develop low-cost diagnostics
and therapies to address the unmet needs.
Segment Analysis
The transthyretin amyloid cardiomyopathy treatment market can be segmented
into tafamidis, diflunisal, and others. Tafamidis is dominating the market
currently as it is the only approved drug for the treatment of transthyretin
amyloid cardiomyopathy. It effectively helps in reducing the formation of
amyloid fibrils and thus prevents damage to heart tissues.
Global Analysis
Regionally, North America holds the largest share in the transthyretin
amyloid cardiomyopathy treatment market due to rising prevalence of heart
diseases and growing awareness. The market in North America is expected to grow
at a significant rate during the forecast period. Europe follows North America.
The market in Europe is likely to witness substantial growth owing to
increasing government spending on healthcare and new product launches. The
market in Asia Pacific is anticipated to be the fastest growing market in the
coming years on account of rapid development of healthcare infrastructure and
research facilities in the region.
Get more insights on Transthyretin Amyloid Cardiomyopathy Treatment Market
